The first miracle in neurodegenerative disease: The discovery of oral levodopa

被引：8
|
作者：
Kordower, JH
Goetz, CG
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA
[2] Rush Presbyterian St Lukes Med Ctr, Res Ctr Brain Repair, Chicago, IL 60612 USA
来源：
BRAIN RESEARCH BULLETIN | 1999年 / 50卷 / 5-6期
关键词：
D O I：
10.1016/S0361-9230(99)00112-4
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
[No abstract available]
引用
收藏
页码：377 / 378
页数：2
相关论文
共 50 条
  • [31] Effects of Oral Levodopa on Balance in People with Idiopathic Parkinson's Disease
    Leroy, Tim
    Baggen, Remco J.
    Lefeber, Nina
    Herssens, Nolan
    Santens, Patrick
    De Letter, Miet
    Maes, Leen
    Bouche, Katie
    Van Bladel, Anke
    JOURNAL OF PARKINSONS DISEASE, 2023, 13 (01) : 3 - 23
  • [32] EFFECT OF AGE ON THE PHARMACOKINETICS OF ORAL LEVODOPA IN PATIENTS WITH PARKINSONS-DISEASE
    CONTIN, M
    RIVA, R
    MARTINELLI, P
    ALBANI, F
    BARUZZI, A
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (05) : 463 - 466
  • [33] Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience
    Thomas, Ilias
    Alam, Moudud
    Bergquist, Filip
    Johansson, Dongni
    Memedi, Mevludin
    Nyholm, Dag
    Westin, Jerker
    JOURNAL OF NEUROLOGY, 2019, 266 (03) : 651 - 658
  • [34] Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson’s disease: a first experience
    Ilias Thomas
    Moudud Alam
    Filip Bergquist
    Dongni Johansson
    Mevludin Memedi
    Dag Nyholm
    Jerker Westin
    Journal of Neurology, 2019, 266 : 651 - 658
  • [35] Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease
    Kostrzewa, RM
    Kostrzewa, JP
    Brus, R
    AMINO ACIDS, 2002, 23 (1-3) : 57 - 63
  • [36] Levodopa: from a discovery to new elaborations
    Katunina, E. A.
    Avakyan, G. N.
    Titova, N. V.
    Bezdolny, Yu. N.
    Malykhina, E. A.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2010, 110 (04) : 97 - 103
  • [37] Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease
    R. M. Kostrzewa
    J. P. Kostrzewa
    R. Brus
    Amino Acids, 2002, 23 : 57 - 63
  • [38] High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease
    Shiraishi, Tomotaka
    Nishikawa, Noriko
    Mukai, Yohei
    Takahashi, Yuji
    PARKINSONISM & RELATED DISORDERS, 2020, 75 : 80 - 84
  • [39] CLINICAL AND PHARMACOKINETIC COMPARISON OF ORAL AND DUODENAL DELIVERY OF LEVODOPA CARBIDOPA IN PATIENTS WITH PARKINSONS-DISEASE WITH A FLUCTUATING RESPONSE TO LEVODOPA
    DELEU, D
    EBINGER, G
    MICHOTTE, Y
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (05) : 453 - 458
  • [40] First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease
    Senek, M.
    Hellstrom, M.
    Albo, J.
    Svenningsson, P.
    Nyholm, D.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 (06): : 727 - 731
12345